Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in PD.

Start Date15 Jun 2024

Sponsor / Collaborator

University of Minnesota

NCT06219915 / CompletedPhase 1/2IIT

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

Start Date15 Mar 2024

Sponsor / Collaborator

University of Michigan

[+1]

NCT05285683 / RecruitingPhase 2IIT

The Role of Dopamine in the Central Neural Signature of Chronic Pain

Chronic pain is associated with plasticity in the brain limbic system composed mainly of the amygdala, hippocampus, ventral striatum, and cingulate cortex (ACC) /medial prefrontal cortex (mPFC). These brain areas, especially the ventral striatum, receive dopaminergic input from the ventral-tegmental area (VTA). Although there is a significant literature now showing that limbic brain tracks chronic pain intensity and predicts the risk of transition from sub-acute to chronic pain, the role of dopaminergic input to the limbic brain and the change thereof which occurs in chronic pain, is still not clear.
Given the role of dopamine in motivational control and the loss of motivation associated with chronic pain understanding how dopaminergic transmission is altered in the limbic brain of chronic pain patients is critical to the understanding of the pathophysiology of chronic pain. Therefore, the overall aim of this project is to use brain imaging to study how dopaminergic transmission through the oral administration of pro-dopaminergic medications carbidopa/levodopa (CD/LD) and methylphenidate will modulate the brain signature of chronic pain. Chronic pain subjects will be scanned twice before and after treatment with the two drugs or placebo. The protocol will follow a randomized double-blind approach.

Start Date02 Feb 2024

Sponsor / Collaborator

University of Rochester

100 Clinical Results associated with Carbidopa

100 Translational Medicine associated with Carbidopa

100 Patents (Medical) associated with Carbidopa

2,717

Literatures (Medical) associated with Carbidopa

01 Mar 2024·Pediatric neurology

Levodopa for Dystonia in Children: A Case Series and Review of the Literature

Review

Author: DeArias, Alexandra Lesenskyj ; Bamford, Nigel S

BACKGROUND:

Levodopa is used to treat hyperkinetic movements in children with dopa-responsive dystonia. However, levodopa may also be helpful in treating other forms of dystonia when used beyond a brief trial period.

METHODS:

We performed a retrospective review of all children referred to our institution for evaluation of generalized dystonia and subsequently treated with carbidopa-levodopa. Motor function was assessed using video recordings and examination notes, quantified with the Burke-Fahn-Marsden Dystonia Rating Scale.

RESULTS:

Long-term treatment with carbidopa-levodopa moderately improved motor function, whereas short-term use did not. Carbidopa-levodopa was well tolerated without untoward effects.

CONCLUSIONS:

Dystonia is a significant cause of disability with limited effective treatment options. Published work is restricted but generally supports the findings of this review. A well-controlled study to examine the utility of carbidopa-levodopa treatment for dystonia is needed.

01 Feb 2024·Journal of aging and physical activity

Immediate Effects of High-Cadence Cycling on Core Outcomes in Individuals With Parkinson’s Disease

Article

Author: Miner, Daniel G ; Chui, Kevin

Despite a strong body of evidence supporting benefits of exercise to reduce severity of motor symptoms of Parkinson’s Disease (PD) over time, research on the immediate impact of exercise as an adjunctive therapy for nonpharmacologic management of motor symptoms and mobility performance in people with PD is limited. The purpose of this study was to examine immediate effects of a single bout of high-cadence cycling on motor symptoms of PD and performance-based outcomes. Twenty individuals with idiopathic PD participated in a pretest/posttest study investigating immediate impacts of a single high-cadence cycling session on performance-based outcomes across multiple domains of motor function, mobility, and balance. Outcomes were analyzed based on time since last dose of levodopa/carbidopa medication. Immediate improvements were observed in motor symptoms of PD with significant improvements in performance across multiple balance systems, dynamic gait, and upper-extremity coordination following a cycling intervention.

30 Jan 2024·mSphere

Microbiota-mediated effects of Parkinson’s disease medications on Parkinsonian non-motor symptoms in male transgenic mice

Article

Author: Cirstea, Mihai ; Bar-Yoseph, Haggai ; Bozorgmehr, Tahereh ; Metcalfe-Roach, Avril ; Finlay, B Brett ; Radisavljevic, Nina ; Tabusi, M Mahebali

ABSTRACT:

Parkinson’s disease (PD) is characterized by motor symptoms and a loss of dopaminergic neurons, as well as a variety of non-motor symptoms, including constipation, depression, and anxiety. Recently, evidence has also accumulated for a link between gut microbiota and PD. Most PD patients are on dopamine replacement therapy, primarily a combination of L-DOPA and carbidopa; however, the effect of these medications on the microbiota and non-motor symptoms in PD is still unclear. In this study, we explored the effects of chronic oral treatment with L-DOPA plus carbidopa (LDCD) on the gut microbiota and non-motor symptoms in males of a transgenic mouse model of PD (dbl-PAC-Tg( SNCAA53T ); Snca -/-). To further test whether the effects of these PD medications were mediated by the gut microbiota, oral antibiotic treatment (Abx; vancomycin and neomycin) was included both with and without concurrent LDCD treatment. Post-treatment, the gastrointestinal, motor, and behavioral phenotypes were profiled, and fecal, ileal, and jejunal samples were analyzed for gut microbiota composition by 16S sequencing. LDCD treatment was found to improve symptoms of constipation and depression in this model, concurrent with increases in Turicibacter abundance in the ileum. Abx treatment worsened the symptoms of constipation, possibly through decreased levels of short-chain fatty acids and disrupted gut barrier function. LDCD + Abx treatment showed an interaction effect on behavioral symptoms that was also associated with ileal Turicibacter levels. This study demonstrates that, in a mouse model, PD medications and antibiotics affect PD-related non-motor symptoms potentially via the gut microbiota.

IMPORTANCE:

The motor symptoms of Parkinson’s disease (PD) are caused by a loss of dopamine-producing neurons and are commonly treated with dopamine replacement therapy (L-DOPA plus carbidopa). PD has also been associated with altered gut microbiota composition. However, the effects of these PD medications on PD-related non-motor symptoms and the gut microbiota have not been well characterized. This study uses a transgenic mouse model of PD to help resolve medication-induced microbiota alterations from those that are potentially disease relevant within a PD context, and explores how long-term treatment may interact with the gut microbiota to impact non-motor symptoms.

120

News (Medical) associated with Carbidopa

24 May 2024

·www.globenewswire.com

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened Improvements in non-motor symptoms correlated with improvements in motor symptoms for Parkinson’s Disease patients May 22, 2024 -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from an oral presentation made yesterday at the XXIX World Congress on Parkinson’s Disease and Related Disorders hosted by the International Association of Parkinsonism and Related Disorders (IAPRD) and held May 19-22, 2024 in Lisbon, Portugal. The presentation Improvement of Motor and Non-Motor Symptoms with Bezisterim Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study was presented on May 21, 2024, and suggest improvements of bezisterim-treated patients with non-motor symptoms. These full dataset findings complement previously reported topline dataset findings of improvement in motor symptoms in patients treated with bezisterim and demonstrate potential intrinsic, levodopa-enhancing activity of bezisterim that is consistent with data from animal models. Patients treated with bezisterim and levodopa/carbidopa experienced a -2.8 point advantage on the Patr III (Motor) score on the Motor Disease Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) compared to patients treated with placebo and levodopa/carbidopa. In patients younger than 70 years old (~50% of patients), the advantage for bezisterim-treated patients was -4.7 points. Furthermore, 30% of bezisterim-treated patients experienced improvement in their ability to move, having Part 3 scores prior to their first morning dose of carbidopa/levodopa that were equal to or better than Part 3 scores associated with their being in the “on” state after carbidopa/levodopa treatment at the start of the study, whereas none of the placebo patients had the similarly improved morning Part 3 scores. The difference was statistically significant (p=0.02). Bezisterim-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159). Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259). More patients on bezisterim had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened. Bezisterim-treated patients experienced an improvement of -0.89 on the urge to move legs/restlessness in legs whereas placebo patients experienced a worsening of +0.99 (p=0.0321). “These full dataset findings suggest that bezisterim as adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue and restlessness of the legs,” stated Joseph Palumbo, BioVie’s Chief Medical Officer. “These findings extend previously reported improvement in motor symptoms with bezisterim and demonstrate potential intrinsic and levodopa-enhancing activity of bezisterim that is consistent with data from animal models and support further clinical investigation of bezisterim in late-phase trials.” Bezisterim (NE3107) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-to-drug interaction. Bezisterim has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFkB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). NE3107 has been shown to modulate the activation of NFkB and thus modulate inflammation. Bezisterim is being investigated for Alzheimer’s disease (AD) and Parkinson’s disease (PD). BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from AD. A Phase 2 study of bezisterim in PD (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration (“FDA”) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultOrphan DrugFast Track

16 May 2024

·www.prnewswire.com

Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson's Disease and Related Disorders

JERSEY CITY, N.J., May 16, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson's Disease and Related Disorders, being held in Lisbon, Portugal, May 19-22. "We are eager to discuss the latest findings from our ongoing Phase 3 BouNDless and Phase 2b BeyoND clinical trials evaluating the efficacy and safety of investigational ND0612 in people with Parkinson's disease experiencing motor fluctuations," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "Our presence at IAPRD this year exemplifies our determination to continue exploring how to address the challenges faced by people living with this disease, including the impact of motor fluctuations." MTPA's posters will be presented during Oral Poster Sessions at the meeting on May 21, 2024 at 9:35 a.m. – 10:20 a.m. WEST. Presentation Details: Presentations include results from the pivotal Phase 3 multi-center, randomized, double-blind double-dummy BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612 in people with PD experiencing motor fluctuations, in addition to three-year outcomes from the Phase 2b open-label BeyoND study (NCT02726386) evaluating the long-term safety of ND0612 in reducing OFF time in people with PD. Continuous subcutaneous levodopa/carbidopa infusion (ND0612) for patients with Parkinson's disease and motor fluctuations: A Phase 3, active-controlled BouNDless stud y (Fabrizio Stocchi, M.D., Ph.D., Institute for Research and Medical Care (IRCCS), San Raffaele, Rome) Oral Poster #O_42 Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson's disease: Three-year data from the open-label BeyoND study (Fabrizio Stocchi, M.D., Ph.D., University San Raffaele Roma and IRCCS San Raffaele) Oral Poster #O_41 About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction and additionally working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to . About NeuroDerm, Ltd. NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at  or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America

Phase 2Phase 3

22 Apr 2024

·www.biospace.com

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24

Pictured: Doctor looking at a patient's brain scans/iStock, Shidlovski With potential U.S. approvals on the line in Parkinson’s disease later this year, AbbVie and NeuroDerm presented promising data for their respective continuous, subcutaneous levodopa infusions at last week’s American Academy of Neurology 2024 annual meeting. Both companies are developing novel delivery systems that allow 24-hour continuous subcutaneous delivery of their drug candidates, which according to Erela Dana, director of neurology at data analytics firm Global Data, could “improve the rate of compliance while reducing risk of motor fluctuations and levodopa-induced complications.” At AAN24, AbbVie showed that its investigational subcutaneous treatment foslevodopa/foscarbidopa could elicit significant improvement in “on” time without troublesome dyskinesia in patients younger than 65 years of age. In Parkinson’s disease, on time refers to periods of good symptom control. However, in those aged 65 years and older, the effect of foslevodopa/foscarbidopa was “numerical” and failed to reach statistical significance, according to AbbVie’s AAN24 abstract. In all other patient subgroups, foslevodopa/foscarbidopa also led to “numerical improvements” in on time without troublesome dyskinesia and “off” time, which refers are the periods when symptoms grow more noticeable and difficult to manage. According to GlobalData, AbbVie also presented long-term safety and tolerability data for foslevodopa/foscarbidopa from an open-label study. Results showed that nearly 84% of treated patients developed at least one adverse event, the most common of which were infusion site erythema and cellulitis. “The success of levodopa infusion systems requires avoidance of infusion-site reactions and reduced discontinuation rates due to safety and tolerability issues,” Dana said, adding that AbbVie’s data “addresses some of these concerns.” AbbVie is developing foslevodopa/foscarbidopa—a combination of prodrugs of levodopa and carbidopa, respectively—for the treatment of motor disturbances in adult patients with advanced Parkinson’s disease. In March 2023, the FDA hit the drug candidate with a Complete Response Letter, requesting additional information regarding its pump system. AbbVie at the time said it planned to resubmit the application. At AAN24, NeuroDerm also presented data from a subgroup analysis of its Parkinson’s disease candidate ND0612, which improved on time without troublesome dyskinesia and had an “overall homogenous” effect when disaggregating patients according to age, sex, baseline disease severity and other factors. Overall, ND0612 was able to improve on time without troublesome dyskinesia by 1.72 hours, according to NeuroDerm’s AAN24 abstract. ND0612 is a drug-device combination therapy that allows the continuous infusion of a levodopa/carbidopa mixture. The investigational product is being developed to treat motor fluctuations in Parkinson’s disease and has a target action date in the second quarter of 2024. While NeuroDerm could beat AbbVie in the race to U.S. commercialization, Dana notes that if both products receive FDA approval real-world evidence and longer-term follow-up data “could provide a competitive edge in the absence of a head-to-head trial.” Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical Result

100 Deals associated with Carbidopa

External Link

KEGG	Wiki	ATC	Drug Bank
D00558	Carbidopa	N04BA03	DB00190

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nausea	US	Aton Pharma, Inc.	25 Apr 1977
Parkinson Disease	US	Aton Pharma, Inc.	25 Apr 1977
Parkinson Disease, Postencephalitic	US	Aton Pharma, Inc.	25 Apr 1977
Parkinson Disease, Secondary	US	Aton Pharma, Inc.	25 Apr 1977
Vomiting	US	Aton Pharma, Inc.	25 Apr 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	Phase 2	US	Chelsea Therapeutics, Inc.	01 Oct 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00983814 (CTgov)	Phase 2	Attention Deficit Disorder With Hyperactivity	20	Carbidopa+Droxidopa (Droxidopa+Carbidopa: Double-Blind)	izreslvbpk(qbxpointpw) = djmoovqczq xxcotmywxp (zkllrlxvxm, kkyliiuqlb - ofwkecsleu) View more	-	18 Apr 2024
				placebo+carbidopa+droxidopa (Placebo: Double-Blind)	izreslvbpk(qbxpointpw) = nwlzdrcucu xxcotmywxp (zkllrlxvxm, cirinkrlkf - qejayoxpuf) View more
NCT04325503 (CTgov)	Phase 1/2	Parkinsonian Disorders	14	Carbidopa+Levodopa	nzzpfxfkui(sjqiopqjje) = afpaudlyin onhxftnkgw (bumvenmgkg, ckkquobjyj - swlxgeagem) View more	-	28 Sep 2023
NCT04380142 (S32.004, CTgov)	Phase 3	Parkinson Disease	174	Placebo+ABBV-951 (LD/CD + Placebo for ABBV-951)	xqjafbgbwk(yqtuvvdxwo) = uohtecxsrm twkssaxiky (ltidnylkbf, ntloxsgtdz - hslxdpphfr) View more	-	18 Nov 2022
				Placebo+ABBV-951 (ABBV-951 + Placebo for LD/CD)	xqjafbgbwk(yqtuvvdxwo) = qtltlqmrcd twkssaxiky (ltidnylkbf, jxtobdwnfw - uwgskfclnq) View more
NCT03362879 (COSMOS, Pubmed) Manual	Not Applicable	Parkinson Disease	401	Carbidopa+levodopa-carbidopa (24-h LCIG)	btlkfqfxdo(wzpwgccwgt) = podafcdlnp xsvywvlfvo (zezdozfejq, 3.8) View more	Positive	17 Aug 2022
				Carbidopa+levodopa-carbidopa (16-h LCIG)	btlkfqfxdo(wzpwgccwgt) = vogsjovhqi xsvywvlfvo (zezdozfejq, 3.3 ) View more
NCT02553265 (CTgov)	Phase 2	Pure Autonomic Failure \| Dysautonomia, Familial	22	Placebo (Placebo)	cbcnaidxax(rzktinftqr) = lfseqrfdjb fpvlywmizv (lxvtymvvey, bzhspyjqfu - sobdksjmjk) View more	-	09 Feb 2022
				Carbidopa Low-Dose (Low-Dose Carbidopa)	cbcnaidxax(rzktinftqr) = ihnakmbkxu fpvlywmizv (lxvtymvvey, ptxvddeeno - dnlhlvtwcs) View more
NCT00685919 (CTgov)	Phase 2/3	Postural Orthostatic Tachycardia Syndrome	32	Placebo (Healthy Participants Who Received Placebo as Treatment A or Treatment B)	wfschczipm(cxnoyokvwh) = unbcmmwuwd coubicgzbq (xvxoatbbko, cqngtgplii - vifnndjqxs) View more	-	20 Sep 2021
				Carbidopa (Healthy Participants Who Received Carbidopa as Treatment A or Treatment B)	wfschczipm(cxnoyokvwh) = icxzylcvab coubicgzbq (xvxoatbbko, rmdnqzrplv - iasebqygks) View more
NTR1616 (AAN2020)	Not Applicable	Parkinson Disease	23	CVT-301 84mg with CD 25mg	zaqoaohelo(hbntcceylf) = 7 (30.4%) in the CVT-301 group vs 1 (4.5%) subject administered oral CD/LD hhdiafdkjx (bjlvzpydza )	Positive	14 Apr 2020
				Oral CD/LD 25/100mg
NCT03115827 (CTgov)	Phase 4	Parkinson Disease	15	Carbidopa+Droxidopa	pbyghpktik(vniqygeksu) = hqmhhrthmj vjuuwsodxv (qldeojlswq, rvzuciooyc - wowtsduaof) View more	-	27 Jan 2020
NCT01399905 (CTgov)	Phase 2	Parkinson Disease	14	Carbidopa (Low-dose Carbidopa (75 mg/Day) Day 1)	szepvnckcr(xumdeicpzb) = wglldvewge cednunryvb (qopobdhoww, ltqgyemsst - tzolzfhbku) View more	-	09 Jan 2020
				Carbidopa (Low-dose Carbidopa (75 mg/Day) Day 2)	szepvnckcr(xumdeicpzb) = doyvucpjkk cednunryvb (qopobdhoww, znaofgzosq - aconbcjguv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis